menu
    • menu
    [{"orgOrder":0,"company":"Camber Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Famotidine","moa":"H2 receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Camber Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Camber Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Camber Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Camber Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pregabalin","moa":"Alpha-2-beta-subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Camber Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Camber Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Camber Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Camber Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Paliperidone Palmitate","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Camber Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Camber Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Camber Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Camber Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Solifenacin Succinate","moa":"M3 receptor","graph1":"Urology","graph2":"Approved FDF","graph3":"Camber Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Camber Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Camber Pharmaceuticals \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Camber Pharmaceuticals

    Menu

    Camber Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Camber Pharmaceuticals

                            U.S.A arrow
                            Vietnam Medi Pharm
                            Not Confirmed

                            Camber Pharmaceuticals

                            U.S.A arrow
                            Vietnam Medi Pharm
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Paliperidone Palmitate

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Camber Pharmaceuticals Launches Generic Invega

                            Details : Paliperidone extended-release tablets are used to treat the symptoms of psychotic disorders, including schizophrenia both as a monotherapy and as an adjunct to mood stabilizers and antidepressants.

                            Product Name : Invega-Generic

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 02, 2024

                            Lead Product(s) : Paliperidone Palmitate

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Camber Pharmaceuticals

                            U.S.A arrow
                            Vietnam Medi Pharm
                            Not Confirmed

                            Camber Pharmaceuticals

                            U.S.A arrow
                            Vietnam Medi Pharm
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Solifenacin Succinate

                            Therapeutic Area : Urology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Camber Pharmaceuticals Launches Generic Vesicare®

                            Details : Solifenacin Succinate, an oral tablet, and generic version of Vesicare, a muscarinic antagonist, is launched to treat symptoms of overactive bladder, such as frequent or urgent urination, and incontinence (urine leakage).

                            Product Name : Vesicare-Generic

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            September 28, 2022

                            Lead Product(s) : Solifenacin Succinate

                            Therapeutic Area : Urology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Camber Pharmaceuticals

                            U.S.A arrow
                            Vietnam Medi Pharm
                            Not Confirmed

                            Camber Pharmaceuticals

                            U.S.A arrow
                            Vietnam Medi Pharm
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Famotidine

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Camber Pharma Launches Generic Pepcid®

                            Details : Pepcid (Famotidine) tablets are a histamine-2 (H ) receptor antagonist indicated in adult and pediatric patients 88lb and greater for the treatment of active duodenal ulcer, active gastric ulcer, symptomatic nonerosive gastroesophageal reflux disease (GE...

                            Product Name : Famotidine-Generic

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 06, 2022

                            Lead Product(s) : Famotidine

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Camber Pharmaceuticals

                            U.S.A arrow
                            Vietnam Medi Pharm
                            Not Confirmed

                            Camber Pharmaceuticals

                            U.S.A arrow
                            Vietnam Medi Pharm
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pregabalin

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Camber Launches Generic Lyrica®

                            Details : Lyrica-Generic (pregabalin) is a calcium channel alpha-2/delta-1 subunit binder, indicated for Neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia & fibromyalgia.

                            Product Name : Lyrica-Generic

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 24, 2020

                            Lead Product(s) : Pregabalin

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth